IP Library Granted Patent US 12,419,967
Granted Patent B2
US 12,419,967 · App. 17/989,526 · Granted Sep 23, 2025

Polyinosinic—polycytidylic acid compositions and methods of making same

Inventors: Mercedes Pozuelo Rubio (Valencia, ES); Marisol Quintero Ortiz (Valencia, ES); Ana Villanueva Garcia (Valencia, ES)
Assignee: HIGHLIGHT THERAPEUTICS, S.L.
A61K47/6935A61K9/0019A61K9/08A61K9/19A61K31/15A61K31/713A61K31/74A61K47/26A61K47/50C07K16/2818C07K16/2827
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,419,967
App. No.
17/989,526
Granted
Sep 23, 2025
Kind
B2
Abstract

The present invention relates to compositions comprising polyinosinic (poly(I)) and polycytidylic acid poly(C) molecules, or a salt and/or solvate thereof, comprising double-stranded polyribonucleotides formed by the respective single-stranded poly(I) and poly(C) molecules and methods of making same. The present invention further relates to compositions wherein the disclosed respective poly(I) and poly(C) single-stranded molecules are annealed to thereby form double-stranded poly(I:C) molecules.

Claims (51)

1. Polyinosinic-polycytidylic acid [poly(I:C)] molecules, or a salt and/or solvate thereof, comprising double-stranded polynucleotides formed by annealing together respective single-stranded poly(I) and poly(C) molecules, wherein

(a) at least 40% of the double-stranded polyribonucleotides comprise at least 850 base pairs, and

(b) at least 50% of the double-stranded polyribonucleotides comprise between 400 and 5000 base pairs.

2. The poly(I:C) molecules of claim 1 , wherein

(a) at least 60% of the double-stranded polyribonucleotides have at least 850 base pairs;

(b) at least 70% of the double-stranded polyribonucleotides have between 400 and 5000 base pairs; and

(c) between 20% and 45% of the double-stranded polyribonucleotides have between 400 and 850 base pairs.

3. The poly(I:C) molecules of claim 1 , wherein

(a) between 5% and 60%, preferably between 10% and 30%, of the double-stranded polyribonucleotides have less than 400 base pairs;

(b) between 20% and 45% or between 15% and 30%, preferably between 20% and 30%, of the double-stranded polyribonucleotides, have between 400 and 850 base pairs;

(c) between 20% and 70%, preferably between 50% and 60%, of the double-stranded polyribonucleotides have between 850 and 5000 base pairs; and

(d) between 0% and 10%, preferably 1% or less, of the double-stranded polyribonucleotides have more than 5000 base pairs.

4. The poly(I:C) molecules of claim 1 , wherein

(a) between 7% and 57% of the double-stranded polyribonucleotides have less than 400 base pairs;

(b) between 20% and 45% of the double-stranded polyribonucleotides have between 400 and 850 base pairs;

(c) between 20% and 70% of the double-stranded polyribonucleotides have between 850 and 5000 base pairs; and

(d) between 0% and 9% of the double-stranded polyribonucleotides have more than 5000 base pairs.

5. A method for producing the poly(I:C) molecules of claim 1 , comprising:

(a) dissolving the poly(I) molecules in PBS to form a first solution;

(b) separately dissolving the poly(C) molecules in PBS to form a second solution;

(c) filtering each respective solution obtained from step (a) and step (b) using a membrane;

(d) concentrating each respective permeate obtained for each respective filtration obtained in step (c) for each respective solution over a membrane to form a respective retentate for each respective solution;

(e) mixing each respective retentate obtained for each respective solution (a) and (b) with a PBS solution;

(f) determining the optical density of each respective retentate obtained in step (e) for each respective solution (a) and (b) and adjusting the total volume to a 1:1 stoichiometry;

(g) combining the respective poly(I) solution with the poly(C) solution obtained at step (e) using heat;

(h) cooling the resulting combined solution to room temperature;

(i) filtering the solution obtained from step (h); and

(j) purifying and desalting the resulting solution.

6. The method of claim 5 , wherein at step (a) and step (b), the poly(I) molecules and the poly(C) molecules are respectively provided as a powder.

7. The method of claim 5 , wherein at step (a) and step (b), the poly(I) molecules and the poly(C) molecules are respectively dissolved at 50° C.

8. The method of claim 5 , wherein at step (c), the filtering membrane comprises a 300 kDa cut-off or a 500 kDa cut-off.

9. The method of claim 5 , wherein the membrane of step (d) is a 30 kDa membrane.

10. The method of claim 5 , wherein the mixing in step (e) is performed using a 10X PBS solution.

11. The method of claim 5 , wherein the combining step (g) is performed at 55-62° C.

12. The method of claim 5 , wherein the filtering step (i) is performed using a G3 glass filter, optionally having a pore size of about 15 μm to 40 μm.

13. The method of claim 5 , wherein the desalting of step (j) is performed using isopropanol.

14. The method of claim 5 , wherein the solution in step (j) is freeze-dried and/or lyophilized at room temperature.

15. The method of claim 5 , wherein

(a) the poly(C) solution of step (b) is heated to a temperature of between 61° C. to 66° C. prior to mixing with the poly(I) solution of step (a); and

(b) the combining of step (g) is performed at a temperature of 55° C. to 58° C., after which the combined mixture is filtered over a 0.2 μm membrane.

16. The composition according to claim 1 , wherein

(a) the single-stranded poly(I) molecules comprise:

(i)<400 bases consist of 80-95% poly(I) molecules,

(ii) 400-850 bases consist of 5-20% poly(I) molecules,

(iii) 850-5000 bases consist of 0-5% poly(I) molecules, and

(iv)>5000 bases consist of 1% or less poly(I) molecules; and

(b) the single-stranded poly(C) molecules comprise:

(i)<400 bases consist of 20-82% poly(C) molecules,

(ii) 400-850 bases consist of 15-40% poly(C) molecules,

(iii) 850-5000 bases consist of 3-50% poly(C) molecules, and

(iv)>5000 bases, consist of 1% or less of poly(C) molecules.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2023
From: POZUELO-RUBIO, MERCEDES; QUINTERO ORTIZ, MARISOL; VILLANUEVA GARCIA, ANA
To: BIONCOTECH THERAPEUTICS, S.L.
Reel/Frame 064946/0504 →
CHANGE OF NAME Recorded Sep 19, 2023
From: BIONCOTECH THERAPEUTICS, S.L.
To: HIGHLIGHT THERAPEUTICS, S.L.
Reel/Frame 064946/0529 →
Priority Claims (1)
EP 15194864 · Nov 17, 2015 · regional
Continuity (4)
Continuation 17095059 · Nov 11, 2020
Continuation 16724519 · Dec 23, 2019
Division 15753328
Related Publication 20230116048A1 · Apr 13, 2023
References Cited (80)
US 10653768B2 · Mutzke et al. · 2020 [cited by applicant]
US 10849921B2 · Quintero Ortiz · 2020 [cited by examiner]
US 10869881B2 · Pozuelo Rubio · 2020 [cited by examiner]
US 11883424B2 · Quintero Ortiz · 2024 [cited by examiner]
US 11896606B2 · Pozuelo Rubio · 2024 [cited by examiner]
US 20090117306A1 · Miyata et al. · 2009 [cited by applicant]
US 20110003883A1 · Lee et al. · 2011 [cited by applicant]
US 20190185859A1 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 20200246451A1 · Mutzke et al. · 2020 [cited by applicant]
CN 102988303 · 2013 [cited by applicant]
CN 103599071 · 2014 [cited by applicant]
WO WO2004045491 · 2004 [cited by applicant]
WO WO2005102278 · 2005 [cited by applicant]
WO WO2008057696 · 2008 [cited by applicant]
WO WO2011003883A1 · 2011 [cited by applicant]
WO WO2011003883 · 2011 [cited by applicant]
WO WO2013040552 · 2013 [cited by applicant]
WO WO2013063019 · 2013 [cited by applicant]
WO WO2013087083 · 2013 [cited by applicant]
WO WO2013087083A1 · 2013 [cited by applicant]
WO WO2013164380 · 2013 [cited by applicant]
WO WO2014057432 · 2014 [cited by applicant]
WO WO2014165296 · 2014 [cited by applicant]
WO WO2015067632 · 2015 [cited by applicant]
WO WO2015173824 · 2015 [cited by applicant]
WO WO2015173824A1 · 2015 [cited by applicant]
U.S. Appl. No. 17/988,625 (Year: 2022). [cited by examiner]
U.S. Appl. No. 18/349,989 (Year: 2023). [cited by examiner]
Hafner A et al., “Particulate formulations for the delivery of poly (I: C) as vaccine adjuvant”. Advanced Drug Delivery Rev. 2013; 65 (10): 1386-1399. [cited by applicant]
Schaffert D et al., “Poly (I: C)-mediated tumor growth suppression in EGF-receptor overexpressing tumors using EGF-polyethylene glycol-linear polyethylenimine as carrier”. Pharm. Res. 2011; 28 (4): 731-741. [cited by applicant]
Kabilova T et al., “Immunotherapy of hepatocellular carcinoma with small double-stranded RNA”. BMC Cancer. 2014; 14: 338. [cited by applicant]
Kübler K et al ., “Immunogenic cell death of human ovarian cancer cells induced by cytosolic poly(I:C) leads to myeloid cell maturation and activates NK cells”. Eur. J. Immunol. 2011; 41 (10): 3028-39. [cited by applicant]
Palchetti S et al., “Structural characterization of cationic liposome/poly(I:C) complexes showing high ability in eliminating prostate cancer cells”. RSC Adv. 2013; 3 (46): 24597-24604. [cited by applicant]
Saheki A et al., “Influence of preparation method on polynucleotide conformation and pharmacological activity of lipoplex”. Int. J. Pharm. 2011; 406 (1-2): 117-21. [cited by applicant]
Chen L et al., “Codelivery of zoledronic acid and doublestranded RNA from core-shell nanoparticles”. INt. J. Nanomed. 2013; 8: 137-145. [cited by applicant]
McBain S et al., “Polyethyleneimine functionalized iron oxide nanoparticles as agents for DNA delivery and transfection”. J. Mater. Chem. 2007; 17 (24): 2561-2565. [cited by applicant]
Cobaleda-Siles M et al., “An Iron Oxide Nanocarrier for dsRNA to Target Lymph Nodes and Strongly Activate Cells of the Immune System”. Small. 2014; 10 (24): 5054-67. [cited by applicant]
Kurosaki T et al., “Ternary complexes of pDNA, polyethylenimine, and γ-polyglutamic acid for gene delivery systems”. Biomaterials. 2009; 30 (14): 2846-2853. [cited by applicant]
Turin-Moleavin I et al., “Dynamic constitutional frameworks (DCFs) as nanovectors for cellular delivery of DNA.”. Org. & Biomol. Chem. 2015; 13: 9005-9011. [cited by applicant]
Bilensoy E, “Cationic nanoparticles for cancer therapy”. Expert Opin. Drug Deliv. 2010; 7 (7): 795-809. [cited by applicant]
Germershaus O and Nultsch K, “Localized, non-viral delivery of nucleic acids: Opportunities, challenges and current strategies”. Asi. J. Pharm. Sci. 2015; 10 (3): 159-175. [cited by applicant]
Islam M et al., “Major degradable polycations as carriers for DNA and siRNA”. Journal of Controlled Release 2014; 193: 75-89. [cited by applicant]
Shabani M et al., “Optimization of Gene Transfection in Murine Myeloma Cell Lines using Different Transfection Reagents”. Avicenna J. Med. Biotech. 2010; 2 (3): 123-130. [cited by applicant]
Pozuelo-Rubio M et al., “BO-110, a dsRNA-Based Anticancer Agent”. Nano-Oncologicals in Adv. De. Sci. Tech. 2014, Springer, pp. 453-470. [cited by applicant]
Tormo D et al., “Targeted Activation of Innate Immunity for Therapeutic Induction of Autophagy and Apoptosis in Melanoma Cells”. Cancer Cell. 2009; 16 (2): 103-114. [cited by applicant]
Bhoopathi P et al., “Pancreatic Cancer-Specific Cell Death Induced In Vivo by Cytoplasmic-Delivered Polyinosine-Polycytidylic Acid”. Cancer Res. 2014; 74 (21): 6224-35. [cited by applicant]
Garcia-Pascual C and Gomez R., “Administration of compound BO-110 reduces neoangiogenesis and cellular proliferation and increases apoptosis in a heterologous mice model of enfometriosis”. J. Endometr. 2013; 5 (suppl. 1… [cited by applicant]
Le U et al., “Tumor chemo-immunotherapy using gemcitabine and a synthetic dsRNA”. Canc. Biol. Ther. 2008; 7 (3): 440-447. [cited by applicant]
Le U et al., “Localized irradiation of tumors prior to synthetic dsRNA therapy enhanced the resultant anti-tumor activity”. Radiother. Oncol. 2009; 90 (2): 273-279. [cited by applicant]
Taura M et al., “TLR3 induction by anticancer drugs potentiates poly I:C—induced tumor cell apoptosis”. Cancer Sci. 2013; 101 (70: 1610-7. [cited by applicant]
Matijevic T et al., “Antitumor Activity from the Combined Application of Poly(I:C) and Chemotherapeutics in Human Metastatic Pharyngeal Cell Lines”. Chemotherapy 2011; 57: 460-7. [cited by applicant]
Levitzki A, “Targeting the immune system to fight cancer using chemical receptor homing vectors carrying polyinosine/cytosine (PolyIC)”. Front. Oncol. 2012; 2: 4. [cited by applicant]
Yoshino H and Kashiwakura I, “Beneficial Effects Of Ionizing Radiation To Enhance Anti-Cancer Effects Of RIG-Like Receptor Stimulus”. Blood 2013; 122:4721. [cited by applicant]
Zhou Y et al., “TLR3 activation efficiency by high or low molecular mass poly I:C”. Innate Immun. 2013; 19 (2): 184-192. [cited by applicant]
Ammi R et al., “Poly(I:C) as cancer vaccine adjuvant: Knocking on the door of medical breakthroughs”. Pharmacol. Ther. 2015; 146:1 20-31. [cited by applicant]
Nagato T and Celis E, “A novel combinatorial cancer immunotherapy”. Oncoimmunology 2014; 3 (5): e28440. [cited by applicant]
Zhang Y et al., “Phosphorothioate modification of the TLR9 ligand CpG ODN inhibits poly (I: C)-induced apoptosis of hepatocellular carcinoma by entry blockade”. Cancer Lett. 2014; 355: 76-84. [cited by applicant]
Ohashi T et al., “Dichloroacetate improves immune dysfunction caused by tumor-secreted lactic acid and increases antitumor immunoreactivity”. Int. J. Cancer. 2013; 133 (5): 1107-18. [cited by applicant]
Chiba Y et al., “IL-27 Enhances the Expression of TRAIL and TLR3 in Human Melanomas and Inhibits Their Tumor Growth in Cooperation with a TLR3 Agonist Poly(I:C) Partly in a TRAIL-Dependent Manner”. PLoSOne 2013; 8: e761… [cited by applicant]
Ho V et al., “TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression”. Oncotarget 2015; 6 (29): 27252-27266. [cited by applicant]
Gupta S et al., “Poly (I:C) enhances the anti-tumor activity of canine parvovirus NS1 protein by inducing a potent anti-tumor immune response”. Tumor Biol. 2016; 37 (9): 12089-12102. [cited by applicant]
Szabo A et al., “Temporally designed treatment of melanoma cells by ATRA and polyl: C results in enhanced chemokine and IFNβ secretion controlled differently by TLR3 and MDA5”. Melanoma Res. 2012; 22 (5): 351-361. [cited by applicant]
Yu L et al., “Polyinosinic—polycytidylic acid inhibits the differentiation of mouse preadipocytes through pattern recognition receptor—mediated secretion of tumor necrosis factor—α ”. Immunol. Cell Biol. 2016; 94 (9): 8… [cited by applicant]
Cho K et al., “Poly I:C primes the suppressive function of human palatine tonsil-derived MSCs against Th17 differentiation by increasing PD-L1 expression”. Immunobiology 2016; 222 (2): 394-398. [cited by applicant]
Vega-Letter A et al., “Differential TLR activation of murine mesenchymal stem cells generates distinct immunomodulatory effects in EAE”. Stem Cell Res. & Ther. 2016; 7: 150. [cited by applicant]
Perrot I et al., “TLR3 and Rig-Like Receptor on Myeloid Dendritic Cells and Rig-Like Receptor on Human NK Cells Are Both Mandatory for Production of IFN-γ in Response to Double-Stranded RNA”. J. Immunol. 2010; 185 (4): … [cited by applicant]
Bald T et al., “Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation”. Cancer Discov. 2014; 4: 674-87. [cited by applicant]
Amos SM et al., “Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice”. Cancer Immunol. Immunother. 2011; 60 (5): 671-83. [cited by applicant]
Sajadian A et al., “Comparing the effect of Toll-like receptor agonist adjuvants on the efficiency of a DNA vaccine”. Arch. Virol. 2014; 159 (8): 1951-1960. [cited by applicant]
Fujimura T et al., “Inhibitory effect of the polyinosinic—polycytidylic acid/cationic liposome on the progression of murine B16F10 melanoma”. Eur. J. Immunol. 2006; 36 (12): 3371-80. [cited by applicant]
Storz U, “Intellectual property protection”. MAbs. 2011; 3 (3): 310-7. [cited by applicant]
Keir M et al., “PD-1 and Its Ligands in Tolerance and Immunity”. Annu. rev. Immunol. 2008; 26: 677-704. [cited by applicant]
Galluzzi L et al., “Classification of current anticancer immunotherapies”. Oncotarget 2014; 5 (24): 12472-508. [cited by applicant]
Vacchelli E et al., “Trial Watch Toll-like receptor agonists for cancer therapy”. Oncoimmunology 2013; 2 (8): e25396, e23510, e25595. [cited by applicant]
Van Der Jeught K et al., “Targeting the tumor microenvironment to enhance antitumor immune responses”. Oncotarget 2015; 6 (3): 1359-81. [cited by applicant]
Ewel C et al., “Polyinosinic-Polycytidylic Acid Complexed with Poly-l-lysine and Carboxymethylcellulose in Combination with Interleukin 2 in Patients with Cancer: Clinical and Immunological Effects”. Cancer Res. 1992; 5… [cited by applicant]
Sanchez-Paulete AR et al., “Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells”. Cancer Discov. 2015; pii: CD-15-0510. [cited by applicant]
Duewell P et al., “Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma”. OnocoImmunol. 2015; 4 (10): e1029698. [cited by applicant]
David Schaffert et al: “Poly(I:C)-Mediated Tumor Growth Suppression in EGF-Receptor Overexpressing Tumors Using EGF-Polyethylene Glycol-Linear Polyethylenimine as Carrier”, Pharmaceutical Research, vol. 28, No. 4, Apr. … [cited by applicant]
Kurosaki T et al: “Ternary complexes of 1-25 pDNA, polyethylenimine, and gamma-polyglutamic acid for gene delivery systems”, Biomaterials, Elsevier Science Publishers BV., Barking, GB, vol. 30, No. 14, May 1, 2009 (May … [cited by applicant]